GLP-1 agonist medications are typically not recommended during pregnancy or breastfeeding due to the limited data on its safety in these cases
At the 24-week mark, patients receiving the drug experienced average weight loss reduction ranging from 7.2% in the 1 mg group to 17.5% in the 12 mg group, compared to 1.6% in the placebo group
Indians, meanwhile, have simply been watching this from the sidelines.Thats because the latest formulations, Novo Nordisk A/Ss Ozempic and Wegovy and Eli Lilly & Cos Mounjaro and Zepbound, wont be available in India anytime soon, amid global supply shortages
Remember that lifestyle changes alongside medication drive the best results across any timeline
Aggressive shaking can create foam and potentially damage the peptide through excessive agitation
For adults who tolerate 2.4 mg for at least four weeks and need additional weight reduction, the current label allows a maximum of 7.2 mg weekly